Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is preferred over older regimens. TAF (tenofovir alafenamide) has significantly lower bone and kidney toxicity compared to TDF (tenofovir disoproxil fumarate) because:

• A TAF is a direct-acting antiviral that bypasses renal tubular cells entirely
• B TAF inhibits the mitochondrial polymerase gamma less than TDF due to a different chemical structure
• C TAF undergoes biliary excretion rather than renal clearance, avoiding tubular toxicity
• D TAF is activated intracellularly within lymphocytes, requiring ~90% lower plasma TDF-equivalent levels — achieving equal intracellular active metabolite (tenofovir diphosphate) while minimizing systemic and renal tubular tenofovir exposure ✓

Explanation

TAF (tenofovir alafenamide) is a prodrug that is stable in plasma and efficiently taken up into lymphocytes (CD4 T cells), where intracellular carboxylesterase-1 cleaves it to tenofovir. This intracellular targeting allows ~90% lower plasma tenofovir concentrations compared to TDF (which is cleaved in plasma and delivers high tenofovir levels systemically). Because proximal renal tubular cells accumulate tenofovir from plasma via OAT1/OAT3 transporters, the lower plasma levels with TAF result in far less renal tubular drug exposure — reducing mitochondrial dysfunction and Fanconi-like proximal tubular injury, and consequently less bone mineral density loss (secondary to reduced phosphate wasting). Intracellular tenofovir diphosphate (the active form) concentrations are equivalent between TAF and TDF, maintaining antiviral efficacy.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.